Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
← catalyst calendarSponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
97actual
Sites
18
Countries
Australia, Netherlands, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-04-11 | actual | When the study began enrolling |
| Primary completion | 2025-11-13 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-10 | actual | The whole study's end, after follow-up |
| First posted | 2019-03-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Cutaneous Squamous Cell Carcinoma
- Basal Cell Carcinoma
Intervention
- Drug: Cemiplimab — also filed as REGN2810, Libtayo
Primary outcomes
what the primary-completion date above is the date OFIncidence, nature, and severity of dose limiting toxicities (DLTs) (if any) graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI CTCAE) v5
measured From the first dose through day 28
Incidence, nature, and severity of treatment-emergent adverse events (TEAEs) graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI CTCAE) v5
measured From the first dose to 90 days after the last dose
Incidence and severity of TEAEs graded according to the NCI CTCAE v5
measured From the first dose up to 90 days after the last dose
The incidence and severity of injection site reactions (ISRs)
measured From the first dose to 90 days after the last dose
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed